SG10201608307WA - Cd3 binding polypeptides - Google Patents

Cd3 binding polypeptides

Info

Publication number
SG10201608307WA
SG10201608307WA SG10201608307WA SG10201608307WA SG10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA
Authority
SG
Singapore
Prior art keywords
binding polypeptides
polypeptides
binding
Prior art date
Application number
SG10201608307WA
Inventor
Philip Huat Tan
Sateesh Kumar Natarajan
Catherine J Mcmahan
Original Assignee
Emergent Product Dev Seattle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Seattle filed Critical Emergent Product Dev Seattle
Publication of SG10201608307WA publication Critical patent/SG10201608307WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201608307WA 2012-04-20 2013-04-18 Cd3 binding polypeptides SG10201608307WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636557P 2012-04-20 2012-04-20
US201261718635P 2012-10-25 2012-10-25
US201361799849P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201608307WA true SG10201608307WA (en) 2016-11-29

Family

ID=49384230

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608307WA SG10201608307WA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides
SG11201406346SA SG11201406346SA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201406346SA SG11201406346SA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Country Status (16)

Country Link
US (1) US10202452B2 (en)
EP (1) EP2839019A4 (en)
JP (2) JP6509724B2 (en)
KR (1) KR20150004856A (en)
CN (1) CN104487587A (en)
AU (2) AU2013249267A1 (en)
BR (1) BR112014025830A8 (en)
CA (1) CA2870545A1 (en)
HK (2) HK1207398A1 (en)
IL (1) IL235093B (en)
IN (1) IN2014MN02293A (en)
MX (1) MX366813B (en)
RU (1) RU2673153C2 (en)
SG (2) SG10201608307WA (en)
UA (1) UA119227C2 (en)
WO (1) WO2013158856A2 (en)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5624276B2 (en) 2006-03-31 2014-11-12 中外製薬株式会社 Methods for controlling blood kinetics of antibodies
JP5334319B2 (en) 2007-09-26 2013-11-06 中外製薬株式会社 Method for modifying isoelectric point of antibody by amino acid substitution of CDR
TWI638833B (en) 2010-11-30 2018-10-21 中外製藥股份有限公司 Cell damage induction treatment
MY171343A (en) 2011-04-22 2019-10-09 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related composition and methods
RU2673153C2 (en) 2012-04-20 2018-11-22 АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи Polypeptides binding to cd3
WO2015046467A1 (en) 2013-09-27 2015-04-02 中外製薬株式会社 Method for producing polypeptide heteromultimer
MX2016009653A (en) * 2014-01-24 2017-03-27 Henry M Jackson Found Advancement Military Medicine Inc Antibodies against f glycoprotein of hendra and nipah viruses.
MX2016017393A (en) 2014-07-01 2017-09-05 Pfizer Bispecific heterodimeric diabodies and uses thereof.
EP3172235A2 (en) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (en) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
PE20171764A1 (en) 2015-01-23 2017-12-21 Sanofi Sa ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES, AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY BIND CD3 AND / OR CD123
JP7082484B2 (en) 2015-04-01 2022-06-08 中外製薬株式会社 Method for Producing Polypeptide Heterogeneous Multimer
TWI787645B (en) 2015-04-13 2022-12-21 美商輝瑞股份有限公司 Cd3-specific antibodies, therapeutic bispecific antibodies and their uses
EP3283520B1 (en) 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
BR112017023692A2 (en) * 2015-05-01 2018-07-17 The Regents Of The University Of California glycan-dependent immunotherapeutic molecules
MX2017014908A (en) 2015-05-21 2018-08-15 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use.
CN104892765B (en) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 A kind of bispecific antibody of AntiCD3 McAb antigen and Her 2 antigen
JOP20160154B1 (en) * 2015-07-31 2021-08-17 Regeneron Pharma Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
CA2999138C (en) * 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017055391A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
BR112018003984A2 (en) 2015-12-09 2018-09-25 Hoffmann La Roche antibodies
RU2746754C2 (en) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Cell damage inducing therapeutic medicinal product for anticancer therapy
US11339225B2 (en) 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN107365387B (en) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 Bispecific antigen binding construct, preparation method and application thereof
KR102530742B1 (en) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. single domain serum albumin binding protein
SG11201810331YA (en) * 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN110603266A (en) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 Type II anti-CD 20 and anti-CD 20/CD3 bispecific antibodies for the treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN106117358A (en) * 2016-06-16 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN106084047A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
CN106084046A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
CN106117361A (en) * 2016-06-17 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN106084048A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
CN106117360A (en) * 2016-06-17 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN106084049A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
CN106146661A (en) * 2016-06-17 2016-11-23 中山大学 AntiCD3 McAb single domain antibody
CN106117359A (en) * 2016-06-17 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN109475603B (en) 2016-06-20 2023-06-13 科马布有限公司 anti-PD-L1 antibodies
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
CN106146662A (en) * 2016-07-18 2016-11-23 中山大学 AntiCD3 McAb single domain antibody
BR112019004873A2 (en) * 2016-09-14 2019-06-11 Teneobio Inc cd3 binding antibodies
US11242400B2 (en) * 2016-09-21 2022-02-08 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
KR102275008B1 (en) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. prostate specific membrane antigen binding protein
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN115028727A (en) 2017-05-12 2022-09-09 哈普恩治疗公司 MSLN-targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
JP7240335B2 (en) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド Anti-BCMA heavy chain only antibody
CN117866097A (en) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 Heavy chain-only anti-BCMA antibodies
CN111201242A (en) * 2017-06-22 2020-05-26 财团法人生物技术开发中心 Asymmetric heterodimeric FC-SCFV fusion anti-GLOBO H and anti-CD 3 bispecific antibodies and uses thereof in cancer therapy
WO2019045856A1 (en) * 2017-08-28 2019-03-07 Systimmune, Inc. Anti-cd3 antibodies and methods of making and using thereof
BR112020007249B1 (en) 2017-10-13 2022-11-22 Harpoon Therapeutics, Inc B-CELL MATURATION ANTIGEN-BINDING ROUTINE, MULTISPECIFIC BINDING PROTEIN AND USE OF SUCH PROTEINS
CN111630070A (en) 2017-10-13 2020-09-04 哈普恩治疗公司 Trispecific proteins and methods of use
CN111629749A (en) 2017-10-18 2020-09-04 诺华股份有限公司 Compositions and methods for selective protein degradation
JP2021502979A (en) 2017-11-15 2021-02-04 ノバルティス アーゲー BCMA targeting chimeric antigen receptor, CD19 targeting chimeric antigen receptor and combination therapy
SG11202005005YA (en) 2017-11-30 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3728319A1 (en) 2017-12-22 2020-10-28 TeneoBio, Inc. Heavy chain antibodies binding to cd22
TW201930591A (en) 2018-01-08 2019-08-01 瑞士商諾華公司 Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3752196A4 (en) 2018-02-15 2022-03-23 MacroGenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN112533950B (en) * 2018-06-29 2023-03-10 多玛医药科技(苏州)有限公司 anti-CD 3e antibodies and uses thereof
WO2020010079A2 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020047452A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
JP2022501031A (en) * 2018-09-19 2022-01-06 フジフィルム セルラー ダイナミクス，インコーポレイテッド Chimeric antigen receptor-modified protein L for activation and expansion of immune cells
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
TWI821474B (en) * 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Cd3 antibody and its pharmaceutical use thereof
WO2020168555A1 (en) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3 antigen binding fragment and application thereof
JP2022523204A (en) 2019-02-25 2022-04-21 ノバルティス アーゲー Mesoporous silica particle composition for virus delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
WO2020252366A1 (en) 2019-06-14 2020-12-17 Teneobio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
CN114761037A (en) 2019-11-26 2022-07-15 诺华股份有限公司 Chimeric antigen receptor binding to BCMA and CD19 and uses thereof
US20230303720A1 (en) 2020-01-13 2023-09-28 Aptevo Research And Development Llc Formulations for protein therapeutics
CN115666639A (en) 2020-01-13 2023-01-31 阿帕特夫研究和发展有限公司 Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
KR20220146530A (en) 2020-02-27 2022-11-01 노파르티스 아게 Methods of Making Chimeric Antigen Receptor-Expressing Cells
US20230174933A1 (en) 2020-02-27 2023-06-08 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2021228783A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceutica Nv Methods for treating multiple myeloma
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
JP2023545057A (en) * 2020-10-07 2023-10-26 ドレン バイオ， インコーポレイテッド Anti-Dectin-1 antibody and its use
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
TW202309294A (en) 2021-04-27 2023-03-01 瑞士商諾華公司 Viral vector production system
JP2024516392A (en) * 2021-04-28 2024-04-15 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Multimerization of binding molecules having antibody constant region variants
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024509664A (en) 2021-04-30 2024-03-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Medication for treatment with anti-CD20/anti-CD3 bispecific antibodies
EP4337794A1 (en) * 2021-05-11 2024-03-20 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
AU2022276523A1 (en) 2021-05-21 2024-01-18 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
AR126838A1 (en) 2021-08-20 2023-11-22 Novartis Ag METHODS FOR PREPARING CELLS THAT EXPRESS CHIMERIC ANTIGEN RECEPTORS
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2024517042A (en) 2022-04-13 2024-04-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Pharmaceutical compositions and methods of use of anti-CD20/anti-CD3 bispecific antibodies
CN115029318B (en) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 Mesenchymal stem cell carrying multi-specific antibody gene and pharmaceutical application thereof
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
ATE277081T1 (en) 1994-01-11 2004-10-15 Dyax Corp HUMAN PLASMIN INHIBITORS DERIVED FROM THE KUNITZ DOMAINS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP4219985B2 (en) 1996-07-23 2009-02-04 タノックス ファーマ ベスローテン フェンノートシャップ Induction of T cell tolerance using soluble molecules capable of simultaneously blocking two costimulatory pathways
AU2719099A (en) 1998-01-23 1999-08-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Multipurpose antibody derivatives
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2002040545A2 (en) * 2000-11-17 2002-05-23 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
RU2179862C1 (en) 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Medicinal preparation to prevent transplant detachment, monoclonal antibody to cd3 antigen of human t-lymphocytes, hybridome and method to treat patients suffering acute transplant detachment reaction following kidney transplantation
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1268394C (en) 2001-01-17 2006-08-09 特鲁比昂药品公司 Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
KR100960560B1 (en) 2002-09-27 2010-06-03 젠코어 인코포레이티드 Optimized fc variants and methods for their generation
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ATE477277T1 (en) 2004-02-16 2010-08-15 Micromet Ag FEWER IMMUNOGENE BINDING MOLECULES
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
JP5686953B2 (en) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Compositions comprising cross-species-specific antibodies and uses of the compositions
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
JP5624276B2 (en) * 2006-03-31 2014-11-12 中外製薬株式会社 Methods for controlling blood kinetics of antibodies
NZ573132A (en) 2006-06-06 2012-05-25 Glaxo Group Ltd Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
KR101571027B1 (en) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Single-chain multivalent binding proteins with effector function
WO2008051448A2 (en) 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
CA2673470A1 (en) 2006-12-21 2008-07-03 Macrogenics, Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
AU2009266856A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc IL6 immunotherapeutics
BRPI0914005A2 (en) 2008-07-02 2015-11-17 Emergent Product Dev Seattle multi-target tnf-alpha antagonist proteins
JP2011526794A (en) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー TGF-β antagonist multi-target binding molecule
EP2321345A1 (en) 2008-07-28 2011-05-18 Emergent Product Development Seattle, LLC Multi-specific binding proteins targeting b cell disorders
BRPI0919382A2 (en) 2008-09-26 2016-01-05 Roche Glycart Ag anti-egfr / anti-igf-1r bispecific antibodies
DK2344540T3 (en) 2008-10-02 2018-01-29 Aptevo Res & Development Llc CD86 ANTAGONIST MULTIMARELY BINDING PROTEINS
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2740098A1 (en) * 2008-10-10 2010-04-15 Valerie Odegard Tcr complex immunotherapeutics
KR101431319B1 (en) 2009-05-27 2014-08-20 에프. 호프만-라 로슈 아게 Tri- or tetraspecific antibodies
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
EP3112382A1 (en) * 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
MY171343A (en) * 2011-04-22 2019-10-09 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related composition and methods
KR101308922B1 (en) * 2012-02-15 2013-09-23 주식회사 경동나비엔 Dual venturi for burner
RU2673153C2 (en) 2012-04-20 2018-11-22 АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи Polypeptides binding to cd3

Also Published As

Publication number Publication date
US20150232557A1 (en) 2015-08-20
HK1208707A1 (en) 2016-03-11
RU2014142166A (en) 2016-06-10
EP2839019A4 (en) 2016-03-30
BR112014025830A2 (en) 2017-06-20
MX2014012578A (en) 2015-05-11
CN104487587A (en) 2015-04-01
IN2014MN02293A (en) 2015-08-07
WO2013158856A2 (en) 2013-10-24
AU2017228643B2 (en) 2019-12-05
CA2870545A1 (en) 2013-10-24
MX366813B (en) 2019-07-25
EP2839019A2 (en) 2015-02-25
US10202452B2 (en) 2019-02-12
HK1207398A1 (en) 2016-01-29
KR20150004856A (en) 2015-01-13
RU2673153C2 (en) 2018-11-22
JP6509724B2 (en) 2019-05-08
JP2015521032A (en) 2015-07-27
IL235093A0 (en) 2014-12-31
AU2013249267A1 (en) 2014-10-23
JP2018138039A (en) 2018-09-06
BR112014025830A8 (en) 2017-10-10
UA119227C2 (en) 2019-05-27
IL235093B (en) 2019-09-26
SG11201406346SA (en) 2014-11-27
AU2017228643A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
HK1208707A1 (en) Cd3 binding polypeptides cd3
IL291571A (en) Cx3cr1-binding polypeptides
HK1210964A1 (en) Immunotherapy with binding agents
HK1212711A1 (en) Bcma antigen binding proteins bcma
HK1204571A1 (en) Protease-regulated antibodies
IL233793B (en) Mica binding agents
AP2014008102A0 (en) Anti-FcRn antibodies
HK1207656A1 (en) Albumin binding polypeptide
AP2015008266A0 (en) 1L-18 binding molecules
EP2875051A4 (en) Anti-siglec-15 antibodies
GB201220474D0 (en) Polypeptides
HK1210793A1 (en) Abd binding polypeptide
PL2928935T3 (en) Binders
HK1210186A1 (en) Anti-h7cr antibodies h7cr
EP2868485A4 (en) Binder
PL2928936T3 (en) Binder
HK1207657A1 (en) Her3 binding polypeptides her3
EP2793918A4 (en) Hdc-sign binding peptides
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201200563D0 (en) Binding molecule
GB201203944D0 (en) Binding polypeptides
GB201103961D0 (en) Binding polypeptides
GB201214293D0 (en) Binding surfaces
PL2641462T3 (en) Binding device
GB201211503D0 (en) Heparin binding peptides